^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AB001

    i
    Other names: AB001, 212Pb-NG001, AB 001, AB-001
    Associations

    News

    Trials
    Company:
    ARTBIO, AlphaGen Therapeutics
    Drug class:
    Alpha radiation emitter, PSMA inhibitor
    Related drugs:
    Associations

    News

    Trials
    1d
    ARTISAN: Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=80, Recruiting, ARTBIO Inc. | Trial completion date: Sep 2033 --> Nov 2028
    Trial completion date
    |
    AB001
    5d
    Cytotoxicity and cell cycle changes in prostate cancer cells with differing PSMA expression and p53 status after treatment with PSMA-targeting radioligand [212Pb]Pb-AB001. (PubMed, Sci Rep)
    Total cell-bound activity, rather than added activity, better predicted radiotoxicity in both TP53-wild-type and TP53-null cell lines, indicating that its therapeutic effect is primarily governed by PSMA-mediated uptake rather than p53 status. These results support the therapeutic potential of [212Pb]Pb-AB001 across cells with varying TP53 status and suggest that combining [212Pb]Pb-AB001 with DNA repair or checkpoint inhibitors may enhance treatment efficacy.
    Journal
    |
    TP53 (Tumor protein P53) • FOLH1 (Folate hydrolase 1)
    |
    TP53 wild-type • FOLH1 expression
    |
    AB001
    22d
    ARTISAN: Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=80, Recruiting, ARTBIO Inc. | Trial primary completion date: Sep 2033 --> Nov 2027
    Trial primary completion date
    |
    AB001
    1m
    ARTISAN: Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=80, Recruiting, ARTBIO Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AB001
    2ms
    ARTISAN: Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=80, Not yet recruiting, ARTBIO Inc.
    New P1 trial
    |
    AB001
    2years
    Phase 0/1 Study of 212Pb-NG001 in mCRPC (clinicaltrials.gov)
    P1, N=3, Completed, ARTBIO Inc. | Recruiting --> Completed | N=23 --> 3
    Trial completion • Enrollment change • Metastases
    |
    AB001
    over2years
    Phase 0/1 Study of 212Pb-NG001 in mCRPC (clinicaltrials.gov)
    P1, N=23, Recruiting, ARTBIO Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    AB001